What Is Tesamorelin? The Stabilized GHRH Analog Explained
Tesamorelin is a stabilized synthetic GHRH analog and the active ingredient of an FDA-approved prescription drug (Egrifta). Here is what it is and how to verify a research COA.
Tesamorelin is a stabilized synthetic analog of growth hormone releasing hormone (GHRH). Notably, it is an FDA-approved medication (marketed as Egrifta for a specific condition), which distinguishes it from most compounds sold in the research peptide market.
Regulatory status
Tesamorelin is the full 44-amino-acid GHRH sequence with a trans-3-hexenoyl group added at the N-terminus for stability. It is approved as a prescription drug under the Egrifta brand; this page does not summarise its effects or uses.
Approved drug versus research-market product
Because Tesamorelin is an approved drug, the regulated pharmaceutical product and the research-market powder are not the same thing. A research-grade product should still carry a credible COA, and buyers should not assume research powder matches pharmaceutical quality without verification.
What to check on a Tesamorelin COA
Confirm a named lab, mass-spec identity, HPLC purity with decimals, a matching batch, a recent date, and endotoxin testing for injectable research preparations.
Frequently Asked Questions
Is Tesamorelin FDA-approved?
Yes, Tesamorelin is approved as a medication (Egrifta) for a specific condition. Research-market powder is a separate product and should still be verified by COA. Nothing here is medical advice.
How is Tesamorelin different from Sermorelin?
Both are GHRH analogs, but Tesamorelin is a stabilized molecule with an approved clinical use, while Sermorelin is a shorter-acting GHRH fragment.
What should a Tesamorelin COA show?
A named lab, mass-spec identity, HPLC purity with decimals, a matching batch, and a recent date, ideally with endotoxin testing.